EBS - Citi likes Intercept Pharma in premarket analyst action September, 04 2019 07:08 AM Emergent Biosolutions Inc. Atreca (NASDAQ:BCEL) initiated with Buy rating and $30 (61% upside) price target at Roth Capital.More news on: Atreca, Inc., Constellation Pharmaceuticals, Inc., Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...